A phase II, multicenter evaluation of docetaxel, gemcitabine, and bevacizumab combination followed by bevacizumab alone in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).

Trial Profile

A phase II, multicenter evaluation of docetaxel, gemcitabine, and bevacizumab combination followed by bevacizumab alone in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2010

At a glance

  • Drugs Bevacizumab; Docetaxel; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 02 Dec 2008 Checked against ClinicalTrials.gov record.
    • 03 Oct 2007 Status change from recruiting to discontinued.
    • 08 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top